Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer.
Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer.
复制标题
DOI：
10.3390/curroncol28030168
复制
发表时间：
2021-05-11
期刊：
影响因子：
--
通讯作者：
Ahmed S
中科院分区：
文献类型：
--
作者：
Andrahennadi S;Sami A;Manna M;Pauls M;Ahmed S
背景：激素受体阳性和her2阴性乳腺癌（HR + BC）是最常见的乳腺癌。内分泌治疗是主要的治疗方法，然而，由于疾病的异质性，对内分泌治疗的抵抗并不罕见。在过去的几十年里，新型靶向治疗联合内分泌治疗的出现改善了HR + BC的预后。本文综述了靶向治疗的现有数据和关键临床试验在HR + BC治疗中的结果。方法：在PubMed和谷歌Scholar中检索HR + BC和靶向治疗相关的关键词进行文献检索。在国际癌症研究会议上发表的主要相关研究也包括在内。结果：他莫昔芬和芳香酶抑制剂的内分泌治疗是早期HR + BC女性的主要治疗方法，可显著降低死亡率。它们也可用于乳腺癌高风险妇女的初级预防。初步数据显示，辅助细胞周期蛋白依赖性激酶（CDK） 4/6抑制剂abemaciclib与芳香酶抑制剂联合治疗高危疾病有效。对于大多数晚期HR + BC的女性，内分泌治疗是主要的治疗方法。最近的证据表明，使用CKD 4/6抑制剂、mTOR抑制剂和PI3K抑制剂联合内分泌治疗与更好的结果和延迟化疗开始相关。目前正在研究几种治疗HR + BC的新型药物。讨论：HR + BC的靶向治疗方案已经发展。未来克服对靶向治疗、新化合物和预测标记物的耐药是改善HR + BC结果的关键。
Background: Hormone receptor-positive and HER2-negative breast cancer (HR + BC) is the most prevalent breast cancer. Endocrine therapy is the mainstay of treatment, however, due to the heterogeneous nature of the disease, resistance to endocrine therapy is not uncommon. Over the past decades, the emergence of novel targeted therapy in combination with endocrine therapy has shown improvement in outcomes of HR + BC. This paper reviews available data of targeted therapy and the results of pivotal clinical trials in the management of HR + BC. Methods: A literature search in PubMed and Google Scholar was performed using keywords related to HR + BC and targeted therapy. Major relevant studies that were presented in international cancer research conferences were also included. Results: Endocrine therapy with tamoxifen and aromatase inhibitors are backbone treatments for women with early-stage HR + BC leading to a significant reduction in mortality. They can also be used for primary prevention in women with a high risk of breast cancer. Preliminary data has shown the efficacy of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor, abemaciclib, in high-risk disease in combination with aromatase inhibitors. For most women with advanced HR + BC, endocrine therapy is the primary treatment. Recent evidence has shown that the use of CKD 4/6 inhibitors, mTOR inhibitors, and PI3K inhibitors in combination with endocrine therapy has been associated with better outcomes and delays initiation of chemotherapy. Several novel agents are under study for HR + BC. Discussion: Targeted treatment options for HR + BC have evolved. The future of overcoming resistance to targeted therapy, novel compounds, and predictive markers are key to improving HR + BC outcomes.
登录
查看更多内容
DOI：
10.1016/j.annonc.2020.10.596
发表时间：
2021-03
期刊：
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子：
--
作者：
Dent S;Cortés J;Im YH;Diéras V;Harbeck N;Krop IE;Wilson TR;Cui N;Schimmoller F;Hsu JY;He J;De Laurentiis M;Sousa S;Drullinsky P;Jacot W
通讯作者：
Jacot W
影响因子：
168.9
作者：
Davies, Christina;Pan, Hongchao;Godwin, Jon;Gray, Richard;Arriagada, Rodrigo;Raina, Vinod;Abraham, Mirta;Medeiros Alencar, Victor Hugo;Badran, Atef;Bonfill, Xavier;Bradbury, Joan;Clarke, Michael;Collins, Rory;Davis, Susan R.;Delmestri, Antonella;Forbes, John F.;Haddad, Peiman;Hou, Ming-Feng;Inbar, Moshe;Khaled, Hussein;Kielanowska, Joanna;Kwan, Wing-Hong;Mathew, Beela S.;Mittra, Indraneel;Mueller, Bettina;Nicolucci, Antonio;Peralta, Octavio;Pernas, Fany;Petruzelka, Lubos;Pienkowski, Tadeusz;Radhika, Ramachandran;Rajan, Balakrishnan;Rubach, Maryna T.;Tort, Sera;Urrutia, Gerard;Valentini, Miriam;Wang, Yaochen;Peto, Richard
通讯作者：
Peto, Richard
DOI：
10.1093/jnci/djt337
发表时间：
2014-01
期刊：
Journal of the National Cancer Institute
影响因子：
--
作者：
Di Leo A;Jerusalem G;Petruzelka L;Torres R;Bondarenko IN;Khasanov R;Verhoeven D;Pedrini JL;Smirnova I;Lichinitser MR;Pendergrass K;Malorni L;Garnett S;Rukazenkov Y;Martin M
通讯作者：
Martin M
影响因子：
168.9
作者：
Davies, C.;Godwin, J.;Gray, R.;Clarke, M.;Darby, S.;McGale, P.;Wang, Y. C.;Peto, R.;Pan, H. C.;Cutter, D.;Taylor, C.;Ingle, J.
通讯作者：
Ingle, J.
DOI：
10.1016/s1470-2045(17)30376-5
发表时间：
2017-07
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Baselga J;Im SA;Iwata H;Cortés J;De Laurentiis M;Jiang Z;Arteaga CL;Jonat W;Clemons M;Ito Y;Awada A;Chia S;Jagiełło-Gruszfeld A;Pistilli B;Tseng LM;Hurvitz S;Masuda N;Takahashi M;Vuylsteke P;Hachemi S;Dharan B;Di Tomaso E;Urban P;Massacesi C;Campone M
通讯作者：
Campone M